MCID: PRM013
MIFTS: 59

Premature Menopause

Categories: Endocrine diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Premature Menopause

MalaCards integrated aliases for Premature Menopause:

Name: Premature Menopause 11 11 14 16 71 75
Primary Ovarian Insufficiency 11 41 43 14 16 75 33
Premature Ovarian Failure 11 75 28 5 14 33
Premature Ovarian Insufficiency 11 5 33
Hypergonadotropic Hypogonadism 11 53 5
Female Hypergonadotropic Hypogonadism 33
Hypergonadotrophic Ovarian Failure 33
Pof - [premature Ovarian Failure] 33
Ovarian Secretion Suppression 33
Primary Female Hypogonadism 33
Ovary Secretion Deficiency 33
Premature Menopause Nos 33
Menopause - Premature 11
Menopause, Premature 43
Menopause Premature 53
Ovary Hyposecretion 33
Menopause Praecox 11
Ovarian Failure 33

Classifications:



External Ids:

Disease Ontology 11 DOID:10787 DOID:5426
ICD9CM 34 256.31
SNOMED-CT 68 154713003 237788002
ICD10 31 E28.3
ICD11 33 756899519
UMLS 71 C0025322 C0085215

Summaries for Premature Menopause

MedlinePlus: 41 What is primary ovarian insufficiency (POI)? Primary ovarian insufficiency (POI), also known as premature ovarian failure, happens when a woman's ovaries stop working normally before she is 40. Many women naturally experience reduced fertility when they are about 40 years old. They may start getting irregular menstrual periods as they transition to menopause. For women with POI, irregular periods and reduced fertility start before the age of 40. Sometimes it can start as early as the teenage years. POI is different from premature menopause. With premature menopause, your periods stop before age 40. You can no longer get pregnant. The cause can be natural or it can be a disease, surgery, chemotherapy, or radiation. With POI, some women still have occasional periods. They may even get pregnant. In most cases of POI, the cause is unknown. What causes primary ovarian insufficiency (POI)? In about 90% of cases, the exact cause of POI is unknown. Research shows that POI is related to problems with the follicles. Follicles are small sacs in your ovaries. Your eggs grow and mature inside them. One type of follicle problem is that you run out of working follicles earlier than normal. Another is that the follicles are not working properly. In most cases, the cause of the follicle problem is unknown. But sometimes the cause may be: Genetic disorders such as Fragile X syndrome and Turner syndrome A low number of follicles Autoimmune diseases, including thyroiditis and Addison disease Chemotherapy or radiation therapy Metabolic disorders Toxins, such as cigarette smoke, chemicals, and pesticides Who is at risk for primary ovarian insufficiency (POI)? Certain factors can raise a woman's risk of POI: Family history. Women who have a mother or sister with POI are more likely to have it. Genes. Some changes to genes and genetic conditions put women at higher risk for POI. For example, women Fragile X syndrome or Turner syndrome are at higher risk. Certain diseases, such as autoimmune diseases and viral infections Cancer treatments, such as chemotherapy and radiation therapy Age. Younger women can get POI, but it becomes more common between the ages of 35-40. What are the symptoms of primary ovarian insufficiency (POI)? The first sign of POI is usually irregular or missed periods. Later symptoms may be similar to those of natural menopause: Hot flashes Night sweats Irritability Poor concentration Decreased sex drive Pain during sex Vaginal dryness For many women with POI, trouble getting pregnant or infertility is the reason they go to their health care provider. What other problems can primary ovarian insufficiency (POI) cause? Since POI causes you to have lower levels of certain hormones, you are at greater risk for other health conditions, including: Anxiety and depression. Hormonal changes caused by POI can contribute to anxiety or lead to depression. Dry eye syndrome and eye surface disease. Some women with POI have one of these eye conditions. Both can cause discomfort and may lead to blurred vision. If not treated, these conditions can cause permanent eye damage. Heart disease. Lower levels of estrogen can affect the muscles lining the arteries and can increase the buildup of cholesterol in the arteries. These factors increase your risk of atherosclerosis (hardening of the arteries). Infertility. Low thyroid function. This problem also is called hypothyroidism. The thyroid is a gland that makes hormones that control your body's metabolism and energy level. Low levels thyroid hormones can affect your metabolism and can cause very low energy, mental sluggishness, and other symptoms. Osteoporosis. The hormone estrogen helps keep bones strong. Without enough estrogen, women with POI often develop osteoporosis. It is a bone disease that causes weak, brittle bones that are more likely to break. How is primary ovarian insufficiency (POI) diagnosed? To diagnose POI, your health care provider may do: A medical history, including asking whether you have relatives with POI A pregnancy test, to make sure that you are not pregnant A physical exam, to look for signs of other disorders which could be causing your symptoms Blood tests, to check for certain hormone levels. You may also have a blood test to do a chromosome analysis. A chromosome is the part of a cell that contains genetic information. A pelvic ultrasound, to see whether or not the ovaries are enlarged or have multiple follicles How is primary ovarian insufficiency (POI) treated? Currently, there is no proven treatment to restore normal function to a woman's ovaries. But there are treatments for some of the symptoms of POI. There are also ways to lower your health risks and treat the conditions that POI can cause: Hormone replacement therapy (HRT). HRT is the most common treatment. It gives your body the estrogen and other hormones that your ovaries are not making. HRT improves sexual health and decreases the risks for heart disease and osteoporosis. You usually take it until about age 50; that's about the age when menopause usually begins. Calcium and vitamin D supplements. Because women with POI are at higher risk for osteoporosis, you should take calcium and vitamin D every day. In vitro fertilization (IVF). If you have POI and you wish to become pregnant, you may consider trying IVF. Regular physical activity and a healthy body weight. Getting regular exercise and controlling your weight can lower your risk for osteoporosis and heart disease. Treatments for associated conditions. If you have a condition that is related to POI, it is important to treat that as well. Treatments may involve medicines and hormones. NIH: National Institute of Child Health and Human Development

MalaCards based summary: Premature Menopause, also known as primary ovarian insufficiency, is related to perrault syndrome and azoospermia, and has symptoms including pelvic pain An important gene associated with Premature Menopause is STAG3 (Stromal Antigen 3), and among its related pathways/superpathways are DNA Damage and Integrated breast cancer pathway. The drugs Ethinylestradiol and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include ovary, bone marrow and thyroid, and related phenotypes are Decreased substrate adherent cell growth and Decreased shRNA abundance

Disease Ontology 11 Premature menopause: An ovarian dysfunction that is the loss of normal ovarian function before age 40.

Primary ovarian insufficiency: An ovarian disease where ovaries do not produce estrogen despite high levels of circulating gonadotropins in women under 40.

Wikipedia: 75 Primary ovarian insufficiency (POI) (also called premature ovarian insufficiency, premature menopause,... more...

Related Diseases for Premature Menopause

Diseases related to Premature Menopause via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 670)
# Related Disease Score Top Affiliating Genes
1 perrault syndrome 32.6 SGO2 NOBOX EIF2B2 CLPB
2 azoospermia 31.5 STAG3 SRD5A2 MSH4 ERCC1 BRDT
3 amenorrhea 31.4 STAG3 NOBOX CYP19A1
4 fanconi anemia, complementation group a 31.3 STAG3 RAD54L NOBOX NBN MSH4 ERCC1
5 hereditary breast ovarian cancer syndrome 30.8 RAD54L NBN ERCC1 CYP19A1 CHEK2
6 alopecia 30.6 TP63 SRD5A2 CYP19A1
7 alopecia, androgenetic, 1 30.6 SRD5A2 CYP19A1
8 blepharophimosis, ptosis, and epicanthus inversus 30.3 NOBOX CYP19A1
9 androgenic alopecia 30.3 SRD5A2 CYP19A1
10 cardiomyopathy, dilated, with hypergonadotropic hypogonadism 11.9
11 osteosclerosis with ichthyosis and premature ovarian failure 11.8
12 premature ovarian failure 17 11.8
13 premature ovarian failure 10 11.7
14 premature ovarian failure 11 11.7
15 moyamoya disease 4 with short stature, hypergonadotropic hypogonadism, and facial dysmorphism 11.7
16 premature ovarian failure 2b 11.7
17 premature ovarian failure 3 11.7
18 premature ovarian failure 6 11.7
19 polyneuropathy-intellectual disability-acromicria-premature menopause syndrome 11.6
20 premature ovarian failure 2a 11.6
21 premature ovarian failure 19 11.6
22 premature ovarian failure 18 11.6
23 primary ovarian insufficiency 6 11.6
24 alopecia-mental retardation syndrome with convulsions and hypergonadotropic hypogonadism 11.5
25 leydig cell hypoplasia 11.5
26 hypogonadism-cataract syndrome 11.5
27 genetic non-acquired premature ovarian failure 11.5
28 primary ovarian insufficiency 9 11.5
29 primary ovarian insufficiency 2a 11.5
30 primary ovarian insufficiency 2b 11.5
31 primary ovarian insufficiency 3 11.5
32 primary ovarian insufficiency 4 11.5
33 primary ovarian insufficiency 5 11.5
34 primary ovarian insufficiency 7 11.5
35 primary ovarian insufficiency 8 11.5
36 primary ovarian insufficiency 10 11.5
37 primary ovarian insufficiency 11 11.5
38 primary ovarian insufficiency 12 11.5
39 primary ovarian insufficiency 13 11.5
40 primary ovarian insufficiency 14 11.5
41 primary ovarian insufficiency 15 11.5
42 primary ovarian insufficiency 16 11.5
43 primary ovarian insufficiency 17 11.5
44 leydig cell hypoplasia, type i 11.5
45 hypogonadism, male, with mental retardation and skeletal anomalies 11.4
46 mikati-najjar-sahli syndrome 11.4
47 hypergonadotropic hypogonadism and partial alopecia 11.4
48 cerebellar ataxia and hypergonadotropic hypogonadism 11.3
49 leukoencephalopathy, progressive, with ovarian failure 11.3
50 marinesco-sjogren syndrome 11.3

Graphical network of the top 20 diseases related to Premature Menopause:



Diseases related to Premature Menopause

Symptoms & Phenotypes for Premature Menopause

UMLS symptoms related to Premature Menopause:


pelvic pain

GenomeRNAi Phenotypes related to Premature Menopause according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.18 BRDT CHEK2 CLPB CYP19A1 EIF2B2 ERCC1
2 no effect GR00402-S-2 10.18 BRDT CHEK2 CLPB CYP19A1 EIF2B2 ERCC1
3 Decreased substrate adherent cell growth GR00193-A-2 9.65 JAK2
4 Decreased substrate adherent cell growth GR00193-A-3 9.65 BRDT CHEK2 JAK2
5 Decreased substrate adherent cell growth GR00193-A-4 9.65 CHEK2
6 Decreased shRNA abundance GR00251-A-1 9.43 CYP19A1
7 Decreased shRNA abundance GR00251-A-2 9.43 CYP19A1
8 Decreased shRNA abundance GR00297-A 9.43 CYP19A1 GALT PMM2 SRD5A2
9 Increased ID2::GFP protein expression GR00211-A 9.16 NBN TP63

MGI Mouse Phenotypes related to Premature Menopause:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10 BRDT CHEK2 CYP19A1 ERCC1 GALT INSL6
2 cellular MP:0005384 9.83 BRDT CHEK2 CYP19A1 ERCC1 GALT INSL6
3 reproductive system MP:0005389 9.47 BRDT CHEK2 CYP19A1 ERCC1 GALT INSL6

Drugs & Therapeutics for Premature Menopause

Drugs for Premature Menopause (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 143)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethinylestradiol Approved Phase 4 57-63-6 5991
2
Lenograstim Approved, Investigational Phase 4 135968-09-1
3
Lactitol Approved, Investigational Phase 4 585-86-4 157355
4
Norethisterone Approved Phase 4 68-22-4 199472 6230
5
Dydrogesterone Approved, Investigational, Withdrawn Phase 4 152-62-5 9051
6 Adjuvants, Immunologic Phase 4
7 Progestins Phase 4
8 Norinyl Phase 4
9
Norethindrone Acetate Phase 4 541197
10
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
11
Testosterone Approved, Investigational Phase 2, Phase 3 58-22-0 5408 6013
12
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
13
Methyltestosterone Approved Phase 2, Phase 3 58-18-4 6010
14
Testosterone undecanoate Approved, Investigational Phase 2, Phase 3 5949-44-0 21873174 65157
15
Testosterone enanthate Approved Phase 2, Phase 3 315-37-7 9416
16
Goserelin Approved Phase 3 65807-02-5 5311128 47725
17
Zoledronic acid Approved Phase 3 118072-93-8 68740
18
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
19
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
20
Metronidazole Approved Phase 3 443-48-1, 69198-10-3 4173
21
Racepinephrine Approved, Vet_approved Phase 2, Phase 3 51-43-4, 329-65-7 838 5816
22
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 3 67-97-0, 1406-16-2 5280795 10883523
23
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 2, Phase 3 8001-79-4 96919
24
Ascorbic acid Approved, Nutraceutical Phase 3 50-81-7 54676860 54670067 5785
25
Black cohosh Experimental Phase 3
26 Hormones Phase 3
27 Estrogens Phase 3
28 Contraceptive Agents Phase 3
29 Vitamins Phase 3
30 Trace Elements Phase 3
31 Micronutrients Phase 3
32 Immunologic Factors Phase 3
33 Contraceptives, Oral, Hormonal Phase 2, Phase 3
34 Contraceptives, Oral Phase 2, Phase 3
35 Anabolic Agents Phase 2, Phase 3
36 Antineoplastic Agents, Hormonal Phase 3
37 Testosterone 17 beta-cypionate Phase 2, Phase 3
38
Triptorelin Pamoate Phase 2, Phase 3
39 Antirheumatic Agents Phase 3
40 Alkylating Agents Phase 3
41 Calcium, Dietary Phase 3
42 Calciferol Phase 3
43 Cathartics Phase 2, Phase 3
44 Castor Phase 2, Phase 3
45 Laxatives Phase 2, Phase 3
46 Gastrointestinal Agents Phase 2, Phase 3
47 Antineoplastic Agents, Alkylating Phase 3
48 Immunosuppressive Agents Phase 3
49
Megestrol Phase 3 3562-63-8 3080587 19090
50 Central Nervous System Stimulants Phase 3

Interventional clinical trials:

(show top 50) (show all 144)
# Name Status NCT ID Phase Drugs
1 Effects of Adipose Derived Stem Cell Therapy in Women With Premature Ovarian Failure Unknown status NCT01853501 Phase 4
2 Autologous Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure Patients. Pilot Study ASCOT-2 Unknown status NCT03535480 Phase 4 G-CSF
3 Filgrastim for Treatment of Premature Ovarian Insufficiency: Randomized Clinical Trial Completed NCT02783937 Phase 4 Saline
4 Comparison of Standard and Physiologic Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure and the Assessment of Skeletal, Cardiovascular and Reproductive Parameters Completed NCT00732693 Phase 4 Ethinylestradiol / Norethisterone;Estradiol / Progesterone
5 The Flexible GnRH Antagonist Protocol Provides Better Results (IVF Outcomes) Than Flare up GnRH Agonist Protocol in Poor Responders Completed NCT00417066 Phase 4 Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands);Arvekap 0.1mg (Triptorelin, Ipsen, France)
6 Estrogen Dosing in Turner Syndrome:Pharmacology & Metabolism Completed NCT00837616 Phase 4 17 B estradiol orally;17 B estradiol
7 A Multi-center Clinical Study on the Efficacy and Safety of Kuntai Capsule Alone and in Combination With Hormones in the Treatment of Early-onset Hypoovarian Function Recruiting NCT05021094 Phase 4 Kuntai Capsule;Femoston
8 Estrogen Replacement in Hypogonadal Girls Treated With GH: Differential Effects of Mode of Estrogen Delivery Completed NCT00140998 Phase 3 17 beta estradiol
9 A Prospective Open Randomized Trial on the Efficacy of Gonadotropin-releasing Hormone Agonist Depot-Triptorelin- to Prevent Chemotherapy Induced Premature Ovarian Failure in Lymphoma Patients. Completed NCT01160315 Phase 2, Phase 3 Triptorelin;Norethisterone acetate
10 Androgen Treatment in Leydig Cell Proliferation Completed NCT01206270 Phase 2, Phase 3 Testosterone undecanoate;Castor Oil
11 Phase III Trial of Intravenous Zoledronic Acid (Zometa) in the Prevention of Bone Loss in Localized Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure Completed NCT00022087 Phase 3 zoledronic acid
12 Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer Completed NCT00068601 Phase 3 cyclophosphamide;goserelin acetate
13 A Phase III Trial of Placebo Versus Megestrol Acetate 20 MG/Day Versus Megestrol Acetate 40 MG/Day as Treatment for Symptoms of Ovarian Failure in Women Treated for Breast Cancer: SWOG Study S9626 Completed NCT00005975 Phase 3 Megestrol Acetate 20mg/day;Megestrol Acetate 40 mg/day;Megestrol Acetate Placebo 20 mg/day;Megestrol Acetate Placebo 40 mg/day
14 Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer Completed NCT01530607 Phase 3 Standard cyclophosphamide;Goserelin (Zoladex)
15 Investigating Reactivation of Ovarian Function Following Autologous PRP Intra-ovarian Infusion in POI Patients Recruiting NCT04031456 Phase 2, Phase 3
16 Investigating the Efficiency of Autologous Platelet Rich Plasma Intraovarian Infusion on Improving Ovarian Functionality in Poor Ovarian Response Patients Recruiting NCT05181748 Phase 2, Phase 3
17 Primary Ovarian Insufficiency: Phenotype and Optimal Treatment Active, not recruiting NCT03568708 Phase 3 Transdermal Estrogen
18 4-step ASCOT in POI Women to Promote Follicular Rescue Active, not recruiting NCT04475744 Phase 3 G-CSF treatment for Bone marrow derived stem cell Mobilization
19 A Randomized Double Blinded Trail of DHEA Supplementation for Treatment of Couples With Normal Hysterosalpingogram and Normal Semen Analysis and Evidence of Premature Ovarian Aging (POA). Terminated NCT00650754 Phase 2, Phase 3
20 Effect of Exercise and Exercise + Phytoestrogen on Bone, Metabolic Syndrome Criteria and Complaints of the Early Menopause Terminated NCT00663104 Phase 3
21 A Randomized Double Blinded Trail of DHEA Supplementation for Treatment of Couples With Premature Ovarian Failure (POF). Terminated NCT00948857 Phase 2, Phase 3
22 Optimal Hormone Replacement for Women With Premature Ovarian Insufficiency Withdrawn NCT02922348 Phase 3 Hormone Replacement Therapy;Combined Oral Contraceptives
23 Human Umbilical Cord Mesenchymal Stem Cells (HUC-MSCs) Transplantation in Women With Primary Ovarian Insufficiency (POI) Unknown status NCT03033277 Phase 1, Phase 2
24 Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure Unknown status NCT02062931 Phase 1, Phase 2
25 Evaluate the Safety and Feasibility of Intra-ovarian Injection of Autologous Adipose Derived Mesenchymal Stromal Cells (ADMSC) in Women With Premature Ovarian Failure(POF) Unknown status NCT02603744 Phase 1, Phase 2
26 Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure Unknown status NCT02043743 Phase 1, Phase 2
27 Transplantation of Specific Populations of Bone Marrow-Derived Stem Cells and Mesenchymal Stem Cells for the Treatment of Premature Ovarian Failure. Unknown status NCT03069209 Phase 1, Phase 2
28 Platelet Rich Plasma Ovarian in Vitro Activation and Stem Cells Transplantation In Women With Ovarian Failure Unknown status NCT04009473 Phase 1, Phase 2
29 A Phase Ι/Π Study of Human Cord Blood Mononuclear Cells and Human Umbilical Cord Mesenchymal Stem Cells Transplantation Combined With Hormone Replacement Therapy in Patients With Premature Ovarian Failure Unknown status NCT01742533 Phase 1, Phase 2 Hormone Replacement Therapy
30 Phase II Study of Goserelin for Ovarian Protection in Premenopausal Patients Receiving Cyclophosphamide Containing Chemotherapy: Menstruation Outcome Unknown status NCT03475758 Phase 2 Goserelin
31 Chinese Medicine(Hu Yang Yang Kun Formula) for Primary Ovarian Insufficiency:Randomized, Double-blind, DHEA-controlled Trial Completed NCT02794948 Phase 1, Phase 2
32 The Safety and Efficacy Assessment of Human Umbilical Cord-derived Mesenchymal Stem Cells (HUC-MSCs) With Injectable Collagen Scaffold Transplantation in Woman With Premature Ovarian Failure (POF) Completed NCT02644447 Phase 1, Phase 2
33 Phase II Study of GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients Completed NCT00429494 Phase 2 Leuprolide Acetate
34 Hormone Replacement in Young Women With Premature Ovarian Failure Completed NCT00001951 Phase 2 TMTDS
35 "It is a Real" The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure Completed NCT02372474 Phase 1, Phase 2
36 Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure (POF) Completed NCT02151890 Phase 1, Phase 2
37 Prospective Randomized Multicenter Study to Prevent Chemotherapy Induced Ovarian Failure With the GnRH-Agonist Goserelin in Young Hormone Insensitive Breast Cancer Patients Receiving Anthracycline Containing (Neo-)Adjuvant Chemotherapy Completed NCT00196846 Phase 2 Goserelin
38 A Randomized Double Blind Control Trial of Transdermal Testosterone Supplementation vs Placebo on Follicular Development and Atresia, Oocyte and Embryo Quality Among Women With Diminished Ovarian Reserve Undergoing in Vitro Fertilization Recruiting NCT01662466 Phase 1, Phase 2 Testosterone cream (0.5mg per gram);Placebo
39 Effects of Immunomodulatory Therapy on Gonadal Function in Women With Autoimmune Premature Ovarian Insufficiency Recruiting NCT05586737 Phase 2 Rituximab
40 Evaluation of the Effect of Pentoxifylline and α-Lipoic Acid as Adjunctive Therapy in Patients With Clomiphene Citrate Resistant Polycystic Ovary Syndrome Recruiting NCT05231980 Phase 2 Pentoxifylline (PTX);Clomiphene Citrate
41 Autologous Heterotopic Fresh Ovarian Graft in Young Woman With Locally Advanced Cervical Cancer Eligible for Pelvic Radiotherapy Treatment Recruiting NCT05462379 Phase 1, Phase 2
42 Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients Enrolling by invitation NCT04536467 Phase 2 Goserelin;Chemotherapy
43 Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency: A Randomized Controlled Trial Not yet recruiting NCT04922398 Phase 1, Phase 2 Normal saline
44 Clinical Study on the Safety and Effectiveness of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency Suspended NCT03816852 Phase 2
45 Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure Terminated NCT00555477 Phase 2 anastrozole
46 Effect of Transdermal Estradiol Replacement Therapy on Ovulation Rate in Women With Premature Ovarian Failure: A Randomized, Placebo-Controlled Trial Withdrawn NCT00370019 Phase 2 Estradiol/Medroxyprogesterone acetate
47 Autologous Very Small Embryonic-like Stem Cells(VSELs) for Premature Ovarian Failure Withdrawn NCT03985462 Phase 1, Phase 2
48 Phase 1, Open-Label, Randomized, Single-Dose, Crossover Bioequivalence And Food Effect Study For A New Formulation Of Premarin Compared With A Reference Tablet In Japanese Healthy Postmenopausal Women Completed NCT01436513 Phase 1 Premarin reference tablet (fasted);Premarin new tablet (fasted);Premarin reference tablet (fed);Premarin new tablet (fed)
49 Autologous Platelet-Rich Plasma (PRP) Infusions and Biomarkers of Ovarian Rejuvenation and Aging Mitigation Completed NCT03178695 Phase 1
50 Clinical Study of Human Umbilical Artery Derived Perivascular Stem Cells in the Treatment of Premature Ovarian Failure Completed NCT05138367 Phase 1

Search NIH Clinical Center for Premature Menopause

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Angelica sinensis preparation
Black Cohosh Extract
Chlorotrianisene
Estradiol
Estradiol acetate
estradiol cypionate
ESTRADIOL PWDR
estradiol valerate
Estrogens
Estrogens, Conjugated (USP)
Estrogens, Esterified (USP)
Estrone
estropipate
Ethinyl Estradiol
polyestradiol
polyestradiol phosphate
Quinestrol
Sodium estrone sulfate
synthetic conjugated estrogens, A
synthetic conjugated estrogens, B

Cochrane evidence based reviews: primary ovarian insufficiency

Genetic Tests for Premature Menopause

Genetic tests related to Premature Menopause:

# Genetic test Affiliating Genes
1 Premature Ovarian Failure 28

Anatomical Context for Premature Menopause

Organs/tissues related to Premature Menopause:

MalaCards : Ovary, Bone Marrow, Thyroid, Eye, Bone, Heart, Breast

Publications for Premature Menopause

Articles related to Premature Menopause:

(show top 50) (show all 6985)
# Title Authors PMID Year
1
Novel STAG3 variant associated with primary ovarian insufficiency and non-obstructive azoospermia in an Iranian consanguineous family. 62 5
35176428 2022
2
Rare missense variant in MSH4 associated with primary gonadal failure in both 46, XX and 46, XY individuals. 62 5
33448284 2021
3
Identification of variants in pleiotropic genes causing "isolated" premature ovarian insufficiency: implications for medical practice. 62 5
29706645 2018
4
Genomic analysis using high-resolution single-nucleotide polymorphism arrays reveals novel microdeletions associated with premature ovarian failure. 62 5
21256485 2011
5
Primary ovarian insufficiency quality of life scale (POIQOLS): development and psychometric properties. 62 41
36443785 2022
6
Melatonin suppresses serum starvation-induced autophagy of ovarian granulosa cells in premature ovarian insufficiency. 62 41
36434569 2022
7
Fertility preservation in the pediatric population-experience from a German Cryobank for ovarian tissue. 62 41
36440191 2022
8
An unbalanced translocation unmasks a recessive mutation in the follicle-stimulating hormone receptor (FSHR) gene and causes FSH resistance. 53 62
20087398 2010
9
Premature menopause in patients with BRCA1 gene mutation. 53 62
16773440 2006
10
Hypergonadotropic hypogonadism and renal failure due to WT1 mutation. 53 62
16476716 2006
11
[Mutations in the follicle-stimulating hormone receptor genes in patients with gonadal dysfunction]. 53 62
11857913 2002
12
Mutations of LH and FSH receptors. 53 62
11079450 2000
13
Aromatase deficiency in a female who is compound heterozygote for two new point mutations in the P450arom gene: impact of estrogens on hypergonadotropic hypogonadism, multicystic ovaries, and bone densitometry in childhood. 53 62
9177373 1997
14
Clinical and hormonal aspects of male hypogonadism in myotonic dystrophy. 53 62
8742989 1996
15
A syndrome of female pseudohermaphrodism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom). 53 62
8200927 1994
16
Role of Ovarian Suppression in Early Premenopausal Breast Cancer. 62
36435615 2023
17
Development of a digital anti-Müllerian hormone immunoassay: ultrasensitive, accurate and practical strategy for reduced ovarian reserve monitoring and assessment. 62
36206626 2023
18
Impact of hormone therapy on the bone density of women with premature ovarian insufficiency: A systematic review. 62
36368093 2023
19
Network and experimental pharmacology on mechanism of Si-Wu-tang improving ovarian function in a mouse model of premature ovarian failure induced by cyclophosphamide. 62
36265674 2023
20
Breast satisfaction in adult women with Turner syndrome-An international survey employing the BREAST-Q questionnaire. 62
35581594 2023
21
LARS2 variants can present as premature ovarian insufficiency in the absence of overt hearing loss. 62
36450801 2022
22
Association of Premature Menopause With Risk of Abdominal Aortic Aneurysm in the Women's Health Initiative. 62
33156064 2022
23
Use of gonadotropin-releasing hormone agonists for ovarian preservation in patients receiving cyclophosphamide for systemic lupus erythematosus: A meta-analysis. 62
36148853 2022
24
The genetic diagnosis of rare endocrine disorders of sex development and maturation: a survey among Endo-ERN centres. 62
36228316 2022
25
Do follicle-stimulating hormone receptor polymorphisms in infertile men influence intracytoplasmic sperm injection outcomes? A prospective cohort study. 62
36134751 2022
26
Wolfram syndrome in a young woman with associated hypergonadotropic hypogonadism - A case report. 62
36100371 2022
27
Association of Coenzyme Q10 with Premature Ovarian Insufficiency. 62
36471220 2022
28
The probability and possible influence factors of intermittent ovarian function recovery in patients with premature ovarian insufficiency. 62
36151013 2022
29
The effect of cognitive-behavioral therapy on stress and anxiety of women with premature ovarian insufficiency: A randomized controlled trial. 62
36269099 2022
30
Sleep, depression, anxiety and fatigue in women with premature ovarian insufficiency. 62
35531877 2022
31
Prdm9 deficiency of rat oocytes causes synapsis among non-homologous chromosomes and aneuploidy. 62
35596034 2022
32
Embryonic stem cells-derived mesenchymal stem cells do not differentiate into ovarian cells but improve ovarian function in POF mice. 62
36265287 2022
33
Maternal exposure to 4-vinylcyclohexene diepoxide during pregnancy induces subfertility and birth defects of offspring in mice. 62
36423845 2022
34
Ultrastructure of human ovarian tissues and risk of cancer cells re-implantation after transplantation to chick embryo chorioallantois membrane (CAM) following vitrification or slow freezing. 62
36417967 2022
35
Clinical and electroencephalographic features of epilepsy in patients with triple X syndrome: A case series. 62
36183453 2022
36
OVARIAN TOXICITY OF FAC CHEMOTHERAPY IN RATS AND POSSIBILITY OF ITS CORRECTION WITH PLATELET-RICH PLASMA. 62
36325707 2022
37
Meiotic recombination: insights into its mechanisms and its role in human reproduction with a special focus on non-obstructive azoospermia. 62
35613017 2022
38
The effect of hematopoietic stem cell transplantation on fertility and strategies for improvement. 62
36038764 2022
39
A prospective, observational study of chemotherapy-induced ovarian damage on follicular reserve and maturation. 62
35833992 2022
40
Gonadotropin-releasing hormone agonist for the preservation of ovarian function in survivors of haematopoietic stem cell transplantation for haematological diseases. 62
36345026 2022
41
Reproductive Outcomes in Young Breast Cancer Survivors Treated (15-39) in Ontario, Canada. 62
36421330 2022
42
DNA Damage Stress Response and Follicle Activation: Signaling Routes of Mammalian Ovarian Reserve. 62
36430860 2022
43
Identification of new variants and candidate genes in women with familial premature ovarian insufficiency using whole-exome sequencing. 62
36208357 2022
44
Determinants of transplantation success with cryopreserved ovarian tissue: data from 196 women of the FertiPROTEKT network. 62
36272106 2022
45
Reproductive health in Turner syndrome: A narrative review. 62
36336873 2022
46
Genomic testing in premature ovarian insufficiency: proceed with caution. 62
35908231 2022
47
Genetic screening in patients with ovarian dysfunction. 62
36373164 2022
48
Expert consensus on fertility preservation in hematopoietic stem cell transplantation in girls in China. 62
36403607 2022
49
An unusual familial Xp22.12 microduplication including EIF1AX: A novel candidate dosage-sensitive gene for premature ovarian insufficiency. 62
36113757 2022
50
Homozygous missense mutation in CCDC155 disrupts the transmembrane distribution of CCDC155 and SUN1, resulting in non-obstructive azoospermia and premature ovarian insufficiency in humans. 62
35587281 2022

Variations for Premature Menopause

ClinVar genetic disease variations for Premature Menopause:

5 (show top 50) (show all 360)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PREPL NM_001171613.2(PREPL):c.614_688delinsTTTTA (p.Lys205fs) INDEL Pathogenic
619046 rs1558502635 GRCh37: 2:44566300-44566374
GRCh38: 2:44339161-44339235
2 overlap with 2 genes DEL Pathogenic
619047 GRCh37: 2:44504991-44580502
GRCh38: 2:44277853-44353364
3 EIF2B2 NM_014239.4(EIF2B2):c.818A>G (p.Lys273Arg) SNV Pathogenic
495050 rs113994016 GRCh37: 14:75473404-75473404
GRCh38: 14:75006701-75006701
4 EIF2B2 NM_014239.4(EIF2B2):c.514C>T (p.Arg172Ter) SNV Pathogenic
495049 rs758398310 GRCh37: 14:75471520-75471520
GRCh38: 14:75004817-75004817
5 NBN NM_002485.5(NBN):c.871C>T (p.Gln291Ter) SNV Pathogenic
495048 rs1554563822 GRCh37: 8:90982617-90982617
GRCh38: 8:89970389-89970389
6 PEX6 NM_000287.4(PEX6):c.371T>C (p.Leu124Pro) SNV Pathogenic
869197 rs1770427781 GRCh37: 6:42946518-42946518
GRCh38: 6:42978780-42978780
7 MSH4 NM_002440.4(MSH4):c.2261C>T (p.Ser754Leu) SNV Pathogenic
869115 rs377712900 GRCh37: 1:76356415-76356415
GRCh38: 1:75890730-75890730
8 TP63 NM_003722.5(TP63):c.1780C>T (p.Arg594Ter) SNV Pathogenic
619065 rs900140738 GRCh37: 3:189612028-189612028
GRCh38: 3:189894239-189894239
9 TP63 NM_003722.5(TP63):c.1794G>A (p.Trp598Ter) SNV Pathogenic
619066 rs1560311010 GRCh37: 3:189612042-189612042
GRCh38: 3:189894253-189894253
10 overlap with 2 genes GRCh38/hg38 2p13.1(chr2:73601366-73673202)x1 CN LOSS Pathogenic
221691 GRCh37: 2:73828493-73900329
GRCh38: 2:73601366-73673202
11 overlap with 30 genes GRCh37/hg19 8p23.1(chr8:8131816-12249050)x1 CN LOSS Pathogenic
221719 GRCh37: 8:8131816-12249050
GRCh38:
12 SGO2 NM_152524.6(SGO2):c.1453_1454del (p.Glu485fs) MICROSAT Pathogenic
375672 rs1057519602 GRCh37: 2:201436519-201436520
GRCh38: 2:200571796-200571797
13 RAD54L NM_003579.4(RAD54L):c.1138C>T (p.Arg380Trp) SNV Pathogenic
929734 rs150138364 GRCh37: 1:46736426-46736426
GRCh38: 1:46270754-46270754
14 BRDT NM_207189.4(BRDT):c.1538del (p.Asp513fs) DEL Pathogenic
929738 rs1188709614 GRCh37: 1:92446523-92446523
GRCh38: 1:91980966-91980966
15 STAG3 NM_001282717.2(STAG3):c.1069C>T (p.Arg357Ter) SNV Pathogenic
929755 rs774733445 GRCh37: 7:99795404-99795404
GRCh38: 7:100197781-100197781
16 JAK2, INSL6 NM_004972.4(JAK2):c.436G>A (p.Asp146Asn) SNV Pathogenic
929762 rs1299892808 GRCh37: 9:5044488-5044488
GRCh38: 9:5044488-5044488
17 GALT NM_000155.4(GALT):c.667C>T (p.Arg223Cys) SNV Pathogenic
529225 rs111033750 GRCh37: 9:34648433-34648433
GRCh38: 9:34648436-34648436
18 SRD5A2 NM_000348.4(SRD5A2):c.704A>T (p.Tyr235Phe) SNV Pathogenic
459644 rs772283403 GRCh37: 2:31751327-31751327
GRCh38: 2:31526257-31526257
19 TP63 NM_003722.5(TP63):c.290G>C (p.Arg97Pro) SNV Pathogenic
1677243 GRCh37: 3:189456529-189456529
GRCh38: 3:189738740-189738740
20 TP63 NM_003722.5(TP63):c.1939C>T (p.Arg647Cys) SNV Pathogenic
1677244 GRCh37: 3:189612187-189612187
GRCh38: 3:189894398-189894398
21 PEX6 NM_000287.4(PEX6):c.2356C>T (p.Arg786Trp) SNV Pathogenic
553552 rs267608239 GRCh37: 6:42933788-42933788
GRCh38: 6:42966050-42966050
22 overlap with 159 genes GRCh37/hg19 Xq22.1-24(chrX:99931059-120328627)x1 CN LOSS Pathogenic
221776 GRCh37: X:99931059-120328627
GRCh38:
23 ERCC1 NM_001983.4(ERCC1):c.466C>T (p.Arg156Trp) SNV Pathogenic
978472 rs757369063 GRCh37: 19:45922415-45922415
GRCh38: 19:45419157-45419157
24 ERCC1 NM_001983.4(ERCC1):c.321+61_525+132del DEL Pathogenic
981245 GRCh37: 19:45922224-45924375
GRCh38: 19:45418966-45421117
25 PMM2 NM_000303.3(PMM2):c.323C>T (p.Ala108Val) SNV Pathogenic
92800 rs200503569 GRCh37: 16:8900240-8900240
GRCh38: 16:8806383-8806383
26 CHEK2 NM_007194.4(CHEK2):c.1169A>C (p.Tyr390Ser) SNV Pathogenic
141818 rs200928781 GRCh37: 22:29091788-29091788
GRCh38: 22:28695800-28695800
27 CLPB NM_001258392.3(CLPB):c.1159C>T (p.Arg387Ter) SNV Pathogenic
187786 rs200203460 GRCh37: 11:72013356-72013356
GRCh38: 11:72302312-72302312
28 CLPB NM_001258392.3(CLPB):c.1167+5G>A SNV Pathogenic
1684623 GRCh37: 11:72013343-72013343
GRCh38: 11:72302299-72302299
29 RAD51C NM_058216.3(RAD51C):c.1090A>G (p.Ser364Gly) SNV Likely Pathogenic
142585 rs587782565 GRCh37: 17:56811542-56811542
GRCh38: 17:58734181-58734181
30 MLH3 NM_001040108.2(MLH3):c.1387A>C (p.Ser463Arg) SNV Likely Pathogenic
836477 rs138974583 GRCh37: 14:75514972-75514972
GRCh38: 14:75048269-75048269
31 POLG NM_002693.3(POLG):c.1685G>A (p.Arg562Gln) SNV Likely Pathogenic
929779 rs781168350 GRCh37: 15:89869870-89869870
GRCh38: 15:89326639-89326639
32 NOTCH2 NM_024408.4(NOTCH2):c.5105G>A (p.Arg1702Gln) SNV Likely Pathogenic
929740 rs999822357 GRCh37: 1:120464967-120464967
GRCh38: 1:119922344-119922344
33 AFF2 NM_002025.4(AFF2):c.3203C>G (p.Ser1068Trp) SNV Likely Pathogenic
929787 rs188208167 GRCh37: X:148048609-148048609
GRCh38: X:148967079-148967079
34 WT1 NM_024426.6(WT1):c.1021A>G (p.Ser341Gly) SNV Likely Pathogenic
929769 rs1852103616 GRCh37: 11:32421586-32421586
GRCh38: 11:32400040-32400040
35 CYP17A1 NM_000102.4(CYP17A1):c.644T>G (p.Val215Gly) SNV Likely Pathogenic
929767 rs1428700861 GRCh37: 10:104594564-104594564
GRCh38: 10:102834807-102834807
36 KHDRBS1 NM_006559.3(KHDRBS1):c.1262C>T (p.Pro421Leu) SNV Likely Pathogenic
929733 rs750291697 GRCh37: 1:32508155-32508155
GRCh38: 1:32042554-32042554
37 DMRT3 NM_021240.4(DMRT3):c.1327C>T (p.Pro443Ser) SNV Likely Pathogenic
929761 rs764103256 GRCh37: 9:990913-990913
GRCh38: 9:990913-990913
38 RYR3 NM_001036.6(RYR3):c.3092A>T (p.Lys1031Met) SNV Likely Pathogenic
461901 rs753104655 GRCh37: 15:33926851-33926851
GRCh38: 15:33634650-33634650
39 BNC1 NM_001717.4(BNC1):c.2273C>T (p.Thr758Ile) SNV Likely Pathogenic
929778 rs760137127 GRCh37: 15:83931730-83931730
GRCh38: 15:83262978-83262978
40 SH2B1 NM_001387430.1(SH2B1):c.1846T>C (p.Ser616Pro) SNV Likely Pathogenic
929780 rs142515048 GRCh37: 16:28883975-28883975
GRCh38: 16:28872654-28872654
41 FANCA NM_000135.4(FANCA):c.3665C>T (p.Pro1222Leu) SNV Likely Pathogenic
929781 rs374537936 GRCh37: 16:89809308-89809308
GRCh38: 16:89742900-89742900
42 SIRT6 NM_016539.4(SIRT6):c.362G>A (p.Arg121His) SNV Likely Pathogenic
929782 rs771714154 GRCh37: 19:4179116-4179116
GRCh38: 19:4179119-4179119
43 ADAMTS1 NM_006988.5(ADAMTS1):c.1304C>A (p.Ser435Tyr) SNV Likely Pathogenic
929783 rs375553171 GRCh37: 21:28213391-28213391
GRCh38: 21:26841072-26841072
44 THBS1 NM_003246.4(THBS1):c.1060C>T (p.Pro354Ser) SNV Likely Pathogenic
929776 rs142519614 GRCh37: 15:39877704-39877704
GRCh38: 15:39585503-39585503
45 MIR4713HG, CYP19A1, PIRC66 NM_000103.4(CYP19A1):c.383A>G (p.His128Arg) SNV Likely Pathogenic
887524 rs375975652 GRCh37: 15:51520044-51520044
GRCh38: 15:51227847-51227847
46 BRWD1 NM_033656.4(BRWD1):c.656G>A (p.Arg219His) SNV Likely Pathogenic
929785 rs372595428 GRCh37: 21:40665912-40665912
GRCh38: 21:39293986-39293986
47 ZNF462 NM_021224.6(ZNF462):c.3515C>G (p.Pro1172Arg) SNV Likely Pathogenic
929764 rs1469441260 GRCh37: 9:109689708-109689708
GRCh38: 9:106927427-106927427
48 NOBOX NM_001080413.3(NOBOX):c.1440G>C (p.Lys480Asn) SNV Likely Pathogenic
929756 rs1006463439 GRCh37: 7:144096072-144096072
GRCh38: 7:144398979-144398979
49 NOS3 NM_000603.5(NOS3):c.172C>T (p.Pro58Ser) SNV Likely Pathogenic
929757 rs752309888 GRCh37: 7:150692304-150692304
GRCh38: 7:150995216-150995216
50 NOS3 NM_000603.5(NOS3):c.505G>A (p.Glu169Lys) SNV Likely Pathogenic
929758 rs765854160 GRCh37: 7:150693936-150693936
GRCh38: 7:150996848-150996848

Copy number variations for Premature Menopause from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 255082 9 72339785 73251640 Duplication TRPM3 Primary ovarian insufficiency
2 257158 X 1 4300000 Duplication PRKX Premature ovarian failure
3 258989 X 129800000 154913754 Copy number Premature ovarian failure
4 261305 X 17100000 56600000 Copy number Premature ovarian failure
5 265094 X 73800000 76000000 Duplication ABCB7 Premature ovarian failure
6 265095 X 73800000 76000000 Duplication ZDHHC15 Premature ovarian failure
7 265096 X 73800000 84500000 Copy number Premature ovarian failure

Expression for Premature Menopause

Search GEO for disease gene expression data for Premature Menopause.

Pathways for Premature Menopause

Pathways related to Premature Menopause according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.49 TP63 RAD54L NBN ERCC1 CHEK2
2 11.31 RAD54L CYP19A1 CHEK2

GO Terms for Premature Menopause

Biological processes related to Premature Menopause according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular response to DNA damage stimulus GO:0006974 9.91 TP63 RAD54L NBN ERCC1 CHEK2
2 t-circle formation GO:0090656 9.71 NBN ERCC1
3 female genitalia development GO:0030540 9.67 SRD5A2 CYP19A1
4 syncytium formation GO:0006949 9.62 ERCC1 CYP19A1
5 testosterone biosynthetic process GO:0061370 9.56 SRD5A2 CYP19A1
6 post-embryonic hemopoiesis GO:0035166 9.46 JAK2 ERCC1
7 double-strand break repair GO:0006302 9.43 RAD54L NBN ERCC1 CHEK2
8 meiotic cell cycle GO:0051321 9.23 STAG3 SGO2 RAD54L NBN MSH4 BRDT

Molecular functions related to Premature Menopause according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 damaged DNA binding GO:0003684 9.1 TP63 NBN ERCC1

Sources for Premature Menopause

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....